Mylan Ireland has signed an agreement to acquire the US commercialisation, marketing and intellectual property rights of Arixtra (fondaparinux sodium) Injection and the authorised generic (AG) of Arixtra from Aspen Global.
Mylan will pay around $225m to Aspen, after completing the transaction, and an additional $75m will be held in escrow and released upon satisfaction of certain conditions.
Go deeper with GlobalData
Subject to certain terms and conditions, Aspen will supply Arixtra and the AG of Arixtra to Mylan.
Mylan CEO Heather Bresch said: "DVT/PE is a serious health concern that is estimated to affect up to 600,000 people in the US.
"The addition of Arixtra is an attractive opportunity to broaden the range of therapeutic categories we market in the US, in both the hospital and retail settings, and bolster our growing portfolio of complex injectables to better meet our customers’ needs."
Arixtra has been developed to treat deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip fracture surgery.
It can also be used to treat persons with thromboembolic complications in hip replacement surgery, knee replacement surgery or abdominal surgery.
As part of an interim distribution arrangement with Aspen, Mylan already is selling Arixtra in the US, while Apotex is currently selling the AG of Arixtra, which is expected to be transferred to Mylan Institutional by year end.
Mylan said that Arixtra and the AG of Arixtra had sales of around $18.8m and $95.3m, for the 12 months ending 30 June.
Mylan produces around 1,300 generic pharmaceuticals and a wide range of antiretroviral therapies.
